Source: Eur Respir J 2007; 29: 548-560
Disease area: Respiratory critical care, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Siempos I. I., Vardakas K. Z., Manta K. G., Falagas M. E.. Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia. Eur Respir J 2007; 29: 548-560

Member's Comments

No comment yet.

Related content which might interest you: Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors Source: Eur Respir J 2010; 35: 598-615 Year: 2010 VAP: approach to therapy Source: Eur Respir Mon 2011; 53: 36-47 Year: 2011 Acinetobacter baumannii infection and colonization among pediatric patients in pediatric ICU and other ICUs Source: International Congress 2018 – Neonatology and paediatric intensive care Year: 2018 Acinetobacter baumani and Pseudomonas aeruginosa drug susceptibility after bacteriological analysis of sputum in patients mechanically ventilated in ICU Source: Eur Respir J 2003; 22: Suppl. 45, 450s Year: 2003 Aetiopathogenesis of VAP revisited Source: Eur Respir Mon 2011; 53: 1-10 Year: 2011 Potential treatment for nosocomial respiratory strains of extreme drug resistant acinetobacter baumanii Source: Eur Respir J 2007; 30: Suppl. 51, 410s Year: 2007 MRSA as a cause of lung infection including airway infection, community-acquired pneumonia and hospital-acquired pneumonia Source: Eur Respir J 2009; 34: 1470-1476 Year: 2009 Hospital-acquired pneumonia: microbiological data and potential adequacy of antimicrobial regimens Source: Eur Respir J 2002; 20: 432-439 Year: 2002 Clinical outcomes of tigecycline in the treatment of critically ill patients with multidrug-resistant Acinetobactor baumannii infection Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011 Prognosis of Acinetobacter baumannii bacteraemia in a respiratory ICU: 10 years‘ experience Source: Eur Respir J 2005; 26: Suppl. 49, 222s Year: 2005 Ventilator-associated pneumonia due to colistin susceptible-only microorganisms Source: Eur Respir J 2007; 30: 307-313 Year: 2007 The mortality of Acinetobacter baumanni infection in intensive care unit Source: Annual Congress 2012 - Infections and sepsis in the ICU Year: 2012 New antibiotics for VAP Source: Eur Respir Mon 2011; 53: 48-53 Year: 2011 Early mortality in patients with community-acquired pneumonia: causes and risk factors Source: Eur Respir J 2008; 32: 733-739 Year: 2008 Aerosolized colistin in critically ill patients for the treatment of ventilator-associated pneumonia, due to multidrug-resistant gram-negative bacteria Source: Eur Respir J 2006; 28: Suppl. 50, 786s Year: 2006 Acinetobacter baumanii and Stenotrophomonas maltophilia are associated with lower airway infections in tracheostomised children and young adults. Source: International Congress 2017 – New insights into paediatric respiratory infections Year: 2017 Prevention of MRSA pneumonia by oral vancomycin decontamination: a randomised trial Source: Eur Respir J 2004; 23: 921-926 Year: 2004 What is MRSA? Source: Eur Respir J 2009; 34: 1190-1196 Year: 2009 An experience of moxifloxacin (MOX) use in therapy of nosocomial pneumonia (NP) in patients who hadn‘t risk factors to be infected by Pseudomonas aeruginosa Source: Eur Respir J 2005; 26: Suppl. 49, 187s Year: 2005 Community-acquired pneumonia due to multidrug and non-multidrug resistant pseudomonas aeruginosa Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016